High-cost specialty drugs as a cost driver have increased the need for cost containment strategies that ensure access but reduce overutilization. The problem is that the market allows pharmaceutical companies to, legally, charge whatever they want.
Margaret E. O’Kane, MHA, referenced the 5000% overnight price hike by Turing Pharmaceuticals for Daraprim, a story that broke the day this panel discussion was filmed in September 2015. While it’s a legal move, it shows companies can essentially charge whatever the market can bear.
“They can charge, right now, more or less whatever they want, and then large payers, like Medicaid, and maybe large health insurers, like the VA, and so forth, can negotiate discounts,” Austin Frakt, PhD, explained. “And that’s just how it plays out. But those prices are going up and up and up, particularly in cancer care.”
He cited a suggestion from Peter Bach, MD, MAPP, of Memorial Sloan Kettering Cancer Center, that instead of paying for a drug, thinking about it as paying for what that drug does for specific diseases. So we would pay for the returns that drug delivers in a certain condition instead of the same price across the board.
This system is similar to what many European countries already do with reference pricing, where they group drugs into therapeutic classes that have similar effect and tag a price for all drugs in that class. The model is a different type of reference pricing than seen in the US, specifically in CalPERS.
However, he acknowledges that while pushing the price lower and lower to address the larger budget impact, we still need to be mindful of encouraging highly cost-effective therapies.
“It’s still possible, though, to have a drug that’s reasonably priced from a cost-effective point of view, but is so widely applicable that the total budget impact is huge,” Dr Frakt said.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More